In the current study, we established the basis for which the flavone, chalcone, and chromone synthetic structures might work as a treatment option for PCa patients with depression by reversibly inhibiting MAO-A and reducing oxidative stress. The gene discussed is MAOA; the disease is depressive symptom measurement.